Product Description
BXCL-502 is a drug candidate for the chronic treatment of agitation in patients with dementia. (Sourced from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-third-quarter-2021-financial)
Mechanisms of Action: GPCR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioXcel
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Dementia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|